In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immuno-Oncology: Halfway To Adulthood

It Has Been A Tremendous Decade For The Immuno-Oncology Field

Executive Summary

Almost a decade on since the first approval for an immuno-oncology therapy, In Vivo analyzes the current landscape, the evolution of combination cancer treatments that use the immune system to target disease and future commercial potential for the market.

You may also be interested in...



Pharma R&D’s COVID-19 Scar

Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.

Pipeline-In-A-Pill: Still A Winning Strategy?

“Pipeline-in-a-pill” has increasingly entered the biopharma executive’s vernacular, denoting an attractive asset that has considerable sales potential owing to the number of discrete patient populations it can target. While the phrase or concept may be in vogue, in reality it is one of the many guises or iterations of lifecycle management.

The Bigger Picture And Global Innovation Hotspots

Focusing too much on the US provides a blinkered view of the industry and prevents access to the myriad opportunities on offer globally. 

Topics

Related Companies

UsernamePublicRestriction

Register

ID1125791

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel